Statin Therapy for The Primary Prevention of Cardiovascular Disease: Pros
Abstract
Cardiovascular disease (CVD) is the leading cause of death worldwide. Dyslipidemia is one of the causes of cardiovascular disease with a contributor to plaque formation.Statins are a class of drugs that lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase. The purpose of statin therapy is to reduce the risk of cardiovascular and associated morbidity and mortality. Statins have a significant impact on reducing atherosclerosis cardiovascular disease. However, primary prevention of ASCVD using statins is debated although statins have several advantages. This review describes the pros of using statins as primary prevention of cardiovascular disease .A comprehensive electronic search was conducted using PubMed, Google Scholar, and ScienceDirect. The search was limited to English-language publications from 2002 to 2021. Hand-searching of relevant journals and reference lists was also performed. It is found that statins can lower cholesterol levels to prevent the formation of atherosclerosis, which then progresses to cardiovascular disease. Recognizing the presence of coronary artery calcium with imaging strategies can guide the initiation of therapy in young adults. Statins have pleiotropic effects to prevent cardiovascular, cost effective, safe, effective, and well tolerated. On the other hand, statins are still debated in older adults. Statins are a primary preventive consideration to reduce morbidity and mortality due to cardiovascular disease.
Keywords: statin, atherosclerosis, primary prevention, and cardiovascular disease
Keywords:
statin, atherosclerosis, primary prevention, cardiovascular diseaseDOI
https://doi.org/10.22270/jddt.v12i5-S.5728References
Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26(1):38–48.
WHO. Cardiovascular Diseases (CVDs) [Internet]. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Grusing S, et al. Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Rockville (MD); 2016.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul;63(25 Pt B):2889–934.
Marcus ME, Manne-goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, et al. Articles Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries : a cross- sectional study of nationally representative , individual-level data. :369–79.
Cho Y, Jeong Y, Seo DH, Ahn SH, Hong S, Suh YJ, et al. Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study. Atherosclerosis. 2021 Jul;328:92–9.
Pletcher MJ, Bibbins-Domingo K, Liu K, Sidney S, Lin F, Vittinghoff E, et al. Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann Intern Med. 2010 Aug;153(3):137–46.
J. SN, C. SS, E. OC, A. RN, Marie NA, S. KS, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults. J Am Coll Cardiol [Internet]. 2022 Mar 1;79(8):819–36. Available from: https://doi.org/10.1016/j.jacc.2021.12.016
Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018 Sep;72(10):1141–56.
Mehta A, Virani SS, Ayers CR, Sun W, Hoogeveen RC, Rohatgi A, et al. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol [Internet]. 2020;76(7):781–93. Available from: https://www.sciencedirect.com/science/article/pii/S0735109720357375
Peter L, Joseph L, M RP, E. FM, Y. HP, Valentin F, et al. Inflammation, Immunity, and Infection in Atherothrombosis. J Am Coll Cardiol [Internet]. 2018 Oct 23;72(17):2071–81. Available from: https://doi.org/10.1016/j.jacc.2018.08.1043
Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. 2017;229–43.
Razavi A, Mehta A, Sperling L. Statin therapy for the primary prevention of cardiovascular disease: Pros. Atherosclerosis. 2022 Jul 1;356.
Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ, et al. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015 Oct;66(15):1657–68.
Razavi AC, Kelly TN, Budoff MJ, Bazzano LA, He J, Fernandez C, et al. Atherosclerotic cardiovascular disease events among statin eligible individuals with and without long-term healthy arterial aging. Atherosclerosis [Internet]. 2021;326:56–62. Available from: https://www.sciencedirect.com/science/article/pii/S0021915021001398
Miedema MD, Dardari ZA, Nasir K, Blankstein R, Knickelbine T, Oberembt S, et al. Association of Coronary Artery Calcium With Long-term, Cause-Specific Mortality Among Young Adults. JAMA Netw Open [Internet]. 2019 Jul 19;2(7):e197440–e197440. Available from: https://doi.org/10.1001/jamanetworkopen.2019.7440
Carr JJ, Jacobs DRJ, Terry JG, Shay CM, Sidney S, Liu K, et al. Association of Coronary Artery Calcium in Adults Aged 32 to 46 Years With Incident Coronary Heart Disease and Death. JAMA Cardiol. 2017 Apr;2(4):391–9.
Dzaye O, Razavi AC, Dardari ZA, Shaw LJ, Berman DS, Budoff MJ, et al. Modeling the Recommended Age for Initiating Coronary Artery Calcium Testing Among At-Risk Young Adults. J Am Coll Cardiol [Internet]. 2021;78(16):1573–83. Available from: https://www.sciencedirect.com/science/article/pii/S0735109721059684
Beatriz LM, Leticia FF, Belén O, Manuel GRJ, Fátima SC, Héctor B, et al. Short-Term Progression of Multiterritorial Subclinical Atherosclerosis. J Am Coll Cardiol [Internet]. 2020 Apr 14;75(14):1617–27. Available from: https://doi.org/10.1016/j.jacc.2020.02.026
Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015 Jul;314(2):142–50.
Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, et al. CHOLESTEROL CLINICAL PRACTICE GUIDELINES 2018 AHA / ACC / AACVPR / AAPA / ABC / ACPM / ADA / AGS / APhA / ASPC / NLA / PCNA Guideline on the Management of Blood Cholesterol Association Task Force on Clinical Practice Guidelines. 2019.
Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr;158(7):526–34.
Saeed A, Mehta LS. Statin Therapy in Older Adults for Primary Prevention of Atherosclerotic Cardiovascular Disease: The Balancing Act. Am Coll Cardiol. 2020;
Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet [Internet]. 2002 Nov 23;360(9346):1623–30. Available from: https://doi.org/10.1016/S0140-6736(02)11600-X
Ridker PM, Lonn E, Paynter NP, Glynn R, Yusuf S. Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. Vol. 135, Circulation. United States; 2017. p. 1979–81.
Published
Abstract Display: 494 
PDF Downloads: 580 PDF Downloads: 27 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.